Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Sep 05
2023
Allogene Therapeutics Announces Participation in September Investor Conference
Learn More >
Aug 14
2023
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Learn More >
Aug 02
2023
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Learn More >
Jul 26
2023
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Learn More >
Jun 15
2023
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Learn More >
Jun 14
2023
Allogene Therapeutics Announces Departure of Chief Financial Officer
Learn More >
Jun 09
2023
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Learn More >
Jun 03
2023
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Learn More >
May 24
2023
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Learn More >
May 11
2023
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Learn More >
View All